{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T11:06:37Z","timestamp":1790247997847,"version":"4.1.0"},"reference-count":45,"publisher":"BioExcel","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DIC"],"abstract":"<jats:p>Pruritus is an early and often debilitating symptom of primary biliary cholangitis (PBC), significantly impairing quality of life through fatigue, sleep disturbance, anxiety and social withdrawal. Traditional management relies on a stepwise approach, with bile acid sequestrants as first-line therapy and rifampin, naltrexone, or sertraline for refractory cases, but these agents often provide incomplete relief and are limited by tolerability and drug\u2013drug interaction concerns. Advances in understanding the mechanisms of cholestatic itch have expanded treatment options to include peroxisome proliferator-activated receptor (PPAR) agonists, such as seladelpar, elafibranor and bezafibrate that uniquely offer both antipruritic effects and improvement in biochemical markers of disease activity. Therapies targeting specific pruritogenic pathways now include ileal bile acid transporter (IBAT) inhibitors, one of which is now approved specifically for PBC-related pruritus, as well as \u03ba-opioid receptor agonists, MrgprX4 antagonists, and autotaxin inhibitors. Optimal management integrates pharmacological therapy with supportive strategies, including skin care, lifestyle modifications and psychosocial support tailored to the individual patient\u2019s disease activity, symptom severity, and comorbidities. By addressing both the biological and experiential dimensions of pruritus, this comprehensive framework enables clinicians to improve symptom control and enhance overall quality of life for patients living with PBC. Emerging therapies and a mechanism-informed treatment approach offer promise for more effective, individualized care in this challenging clinical context.\n\nDownload the Plain Language Summary of this article: https:\/\/www.drugsincontext.com\/plain-language-summaries\/plain-language-summary-new-and-emerging-treatments-for-pbc-related-pruritus<\/jats:p>","DOI":"10.7573\/dic.2025-12-3","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T09:14:30Z","timestamp":1779095670000},"page":"1","source":"Crossref","is-referenced-by-count":0,"title":["New and emerging treatments for PBC-related pruritus"],"prefix":"10.7573","volume":"15","author":[{"given":"Sarah L","family":"Anderson","sequence":"first","affiliation":[{"name":"PeerView Institute for Medical Education, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10047","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"1.\tTanaka A, Ma X, Takahashi A, Vierling JM. Primary biliary cholangitis. Lancet. 2024;404(10457):1053\u20131066. https:\/\/doi. org\/10.1016\/S0140-6736(24)01303-5","DOI":"10.1016\/S0140-6736(24)01303-5"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"2.\tBrown CL, Bajaj JS. Considerations in the diagnoses and management of hepatic disease in older adults. Am J Gastroenterol. 2025;120(Suppl. 10):S56\u2013S66. https:\/\/doi.org\/10.14309\/ajg.0000000000003641.07","DOI":"10.14309\/ajg.0000000000003641.07"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"3.\tChoi G, Jesudian AB, Saab S. Optimizing care in primary biliary cholangitis: current treatments and the second-line decision. Dig Dis Sci. 2025. https:\/\/doi.org\/10.1007\/s10620-025-09537-3","DOI":"10.1007\/s10620-025-09537-3"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"4.\tLevy C, Bowlus CL. Primary biliary cholangitis: personalizing second-line therapies. Hepatology. 2025;82(4):895\u2013910. https:\/\/doi.org\/10.1097\/HEP.0000000000001166","DOI":"10.1097\/HEP.0000000000001166"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"5.\tLindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2019;69(1):394\u2013419. https:\/\/doi.org\/10.1002\/ hep.30145","DOI":"10.1002\/hep.30145"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"6.\tEuropean Association for the Study of the Liver. EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67(1):145\u2013172. https:\/\/doi.org\/10.1016\/j.jhep.2017.03.022","DOI":"10.1016\/j.jhep.2017.03.022"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"7.\tHirschfield GM, Bowlus CL, Mayo MD, et al. A phase 3 trial of seladelpar in primary biliary cholangitis. N Engl J Med. 2024;390(9):783\u2013794. https:\/\/doi.org\/10.1056\/NEJMoa2312100","DOI":"10.1056\/NEJMoa2312100"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"8.\tKowdley KV, Bowlus CL, Levy C, et al. Efficacy and safety of elafibranor in primary biliary cholangitis. N Engl J Med. 2024;390(9):795\u2013805. https:\/\/doi.org\/10.1056\/NEJMoa2306185","DOI":"10.1056\/NEJMoa2306185"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"9.\tHirschfield GM, Bowlus CL, Jones DEJ, et al. Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2026;11(1):22\u201333. https:\/\/doi.org\/10.1016\/S2468-1253(25)00192-X","DOI":"10.1016\/S2468-1253(25)00192-X"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"10.\tGabrielli F, Crepaldi E, Cavicchioli A, et al. A comprehensive review of cholestatic pruritus treatments. Biomolecules. 2024;14(10):1227. https:\/\/doi.org\/10.3390\/biom14101227","DOI":"10.3390\/biom14101227"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"11.\tBeuers U, Wolters F, Oude Elferink RPJ. Mechanisms of pruritus in cholestasis: understanding and treating the itch. Nat Rev Gastroenterol Hepatol. 2023;20(1):26\u201336. https:\/\/doi.org\/10.1038\/s41575-022-00687-7","DOI":"10.1038\/s41575-022-00687-7"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"12.\tBeuers U, Kremer AE, Bolier R, Oude Elferink RPJ. Pruritus in cholestasis: facts and fiction. Hepatology. 2014;60(1):399- 407. https:\/\/doi.org\/10.1002\/hep.26909","DOI":"10.1002\/hep.26909"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"13.\tKremer AE, Martens JJWW, Kulik W, et al. Lysophosphatidic acid is a potential mediator of cholestatic pruritus. Gastroenterology. 2010;139(3):1008\u20131018. https:\/\/doi.org\/10.1053\/j.gastro.2010.05.009","DOI":"10.1053\/j.gastro.2010.05.009"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"14.\tKremer AE, van Dijk R, Leckie P, et al. Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions. Hepatology. 2012;56(4):1391\u20131400. https:\/\/doi.org\/10.1002\/hep.25748","DOI":"10.1002\/hep.25748"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"15.\tChen Y, Wang Z-L, Yeo M, et al. Epithelia-sensory neuron cross talk underlies cholestatic itch induced by lysophosphatidylcholine. Gastroenterology. 2021;161(1):301\u2013317.e16. https:\/\/doi.org\/10.1053\/j.gastro.2021.03.049","DOI":"10.1053\/j.gastro.2021.03.049"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"16.\tVander Dose A, Levy C, Yosipovitch G. Cholestatic itch: our current understanding of pathophysiology and treatments. Am J Clin Dermatol. 2022;23(5):647\u2013659. https:\/\/doi.org\/10.1007\/s40257-022-00710-2","DOI":"10.1007\/s40257-022-00710-2"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"17.\tCarey EJ, Ali AH, Lindor KD. Primary biliary cirrhosis. Lancet. 2015;386(10003):1565\u20131575. https:\/\/doi.org\/10.1016\/S0140- 6736(15)00154-3","DOI":"10.1016\/S0140-6736(15)00154-3"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"18.\tRogal SS, Hansen L, Patel A, et al. AASLD practice guidance: palliative care and symptom-based management in decompensated cirrhosis. Hepatology. 2022;76(3):819\u2013853. https:\/\/doi.org\/10.1002\/hep.32378","DOI":"10.1002\/hep.32378"},{"key":"ref18","unstructured":"19.\tEuropean Medicines Agency. Reflection paper on regulatory requirements for the development of medicinal products for primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC). https:\/\/www.ema.europa.eu\/ en\/documents\/scientific-guideline\/reflection-paper-regulatory-requirements-development-medicinal-products-primary-biliary-cholangitis-pbc-primary-sclerosing-cholangitis-psc_en.pdf. Accessed May 13, 2026."},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"20.\tMedina-Morales E, Barba Bernal R, Gerger H, et al. Pharmacological therapy of pruritus in primary biliary cholangitis: a systematic review and meta-analysis of randomized clinical trials. J Clin Gastroenterol. 2023;57(2):143\u2013152. https:\/\/doi.org\/10.1097\/MCG.0000000000001797","DOI":"10.1097\/MCG.0000000000001797"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"21.\tLutz JD, Kirby BJ, Wang L, et al. Cytochrome P450 3A induction predicts P-glycoprotein induction; Part 1: establishing induction relationships using ascending dose rifampin. Clin Pharmacol Ther. 2018;104(6):1182\u20131190. https:\/\/doi. org\/10.1002\/cpt.1073","DOI":"10.1002\/cpt.1073"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"22.\tBergasa NV, Talbot TL, Alling DW, et al. A controlled trial of naloxone infusions for the pruritus of chronic cholestasis. Gastroenterology. 1992;102(2):544\u2013549. https:\/\/doi.org\/10.1016\/0016-5085(92)90102-5","DOI":"10.1016\/0016-5085(92)90102-5"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"23.\tMayo MJ, Handem I, Saldana S, Jacobe H, Getachew Y, Rush AJ. Sertraline as a first-line treatment for cholestatic pruritus. Hepatology. 2007;45(3):666\u2013674. https:\/\/doi.org\/10.1002\/hep.21553","DOI":"10.1002\/hep.21553"},{"key":"ref23","unstructured":"24.\tLevy C, Kremer AE, Skalicky AM, et al. Clinically meaningful change of pruritus numeric rating scale in adults with primary biliary cholangitis with moderate to severe pruritus. In: EASL 2025 conference reports. https:\/\/www.natap. org\/2025\/EASL\/EASL_103.htm. Accessed March 22, 2026."},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"25.\tde Vries E, Boiler R, Goet J, et al. Fibrates for Itch (FITCH) in fibrosing cholangiopathies: a double-blind, randomized, placebo-controlled trial. Gastroenterology. 2021;160(3):734\u2013743.e6. https:\/\/doi.org\/10.1053\/j.gastro.2020.10.001","DOI":"10.1053\/j.gastro.2020.10.001"},{"key":"ref25","unstructured":"26.\tUS Food and Drug Administration. Highlights of prescribing information: IQIRVO (elafibranor) tablets. FDA; 2024. https:\/\/www.fda.gov\/media\/180873\/download. Accessed May 13, 2026."},{"key":"ref26","unstructured":"27.\tEuropean Medicines Agency. Iqirvo (elafibranor) \u2013 EPAR Product Information. https:\/\/www.ema.europa.eu\/en\/ medicines\/human\/EPAR\/iqirvo. Accessed May 13, 2026."},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"28.\tOlveira A, Levy C, Akarca U, et al. Long-term treatment with elafibranor leads to biochemical and symptomatic improvements for at least 3 years in patients with primary biliary cholangitis. Gastroenterol Hepatology. 2026;49(Suppl. 1):113349. https:\/\/doi.org\/10.1016\/S0210-5705(26)00564-9","DOI":"10.1016\/S0210-5705(26)00564-9"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"29.\tBrown CL, Bajaj JS. Considerations in the diagnoses and management of hepatic disease in older adults. Am J Gastroenterol. 2025;120(Suppl. 10):S56\u2013S66. https:\/\/doi.org\/10.14309\/ajg.0000000000003641.07","DOI":"10.14309\/ajg.0000000000003641.07"},{"key":"ref29","unstructured":"30.\tUS Food and Drug Administration. LIVDELZI (seladelpar) capsules [package insert]. FDA; 2024. https:\/\/www. accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/217899s000lbl.pdf. Accessed December 8, 2025."},{"key":"ref30","unstructured":"31.\tEuropean Medicines Agency. Lyvdelzi (seladelpar) \u2013 EPAR summary for the public. https:\/\/www.ema.europa.eu\/en\/ medicines\/human\/EPAR\/lyvdelzi. Accessed May 13, 2026."},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"32.\tKremer AE, Mayo MJ, Hirschfield GM, et al. Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis. Hepatology. 2024;80(1):27\u201337. https:\/\/doi.org\/10.1097\/HEP.0000000000000728","DOI":"10.1097\/HEP.0000000000000728"},{"key":"ref32","unstructured":"33.\tLevy C, Trivedi PJ, Kowdley KV, et al. Long-term efficacy and safety of selective PPAR\u03b4 agonist seladelpar in primary biliary cholangitis: ASSURE interim study results. Am J Gastroenterol. 2025. https:\/\/doi.org\/10.14309\/ ajg.0000000000003603"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"34.\tHirschfield G, Kremer A, Levy C, et al. Sustained and clinically meaningful improvements in moderate to severe pruritus in patients with primary biliary cholangitis treated with seladelpar: results from the ASSURE study up to 30 months. Dig Liver Dis. 2026;58(Suppl. 1):S64. https:\/\/doi.org\/10.1016\/j.dld.2026.01.107","DOI":"10.1055\/s-0046-1826592"},{"key":"ref34","unstructured":"35.\tLinerixibat lands FDA first for cholestatic pruritus in primary biliary cholangitis. https:\/\/www.healio.com\/news\/ gastroenterology\/20260319\/linerixibat-lands-fda-first-for-cholestatic-pruritus-in-primary-biliary-cholangitis. Accessed March 22, 2026."},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"36.\tHirschfield GM, Bowlus CL, Jones DE, et al. Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2026;11(1):22\u201333. https:\/\/doi.org\/10.1016\/S2468-1253(25)00192-X","DOI":"10.1016\/S2468-1253(25)00192-X"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"37.\tLevy C, Kenrick S, Bowlus CL, et al. GLIMMER: a randomized phase 2b dose-ranging trial of linerixibat in primary biliary cholangitis patients with pruritus. Clin Gastroenterol Hepatol. 2023;21(7):1902\u20131912.e13. https:\/\/doi.org\/10.1016\/j. cgh.2022.10.032","DOI":"10.1016\/j.cgh.2022.10.032"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"38.\tKaratza E, Swift B, Carreno F, et al. Serum bile acid change correlates with improvement in pruritus in patients with primary biliary cholangitis receiving linerixibat. Liver Int. 2024;44(9):2293\u20132302. https:\/\/doi.org\/10.1111\/liv.15982","DOI":"10.1111\/liv.15982"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"39.\tCancado GGGL, Lleo A, Levy C, Trauner M, Hirschfield GM. Primary biliary cholangitis and the narrowing gap towards optimal disease control. Lancet Gastroenterol Hepatol. 2025;10(9):855\u2013870. https:\/\/doi.org\/10.1016\/S2468- 1253(25)00025-1","DOI":"10.1016\/S2468-1253(25)00025-1"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"40.\tCarreno F, Karatza E, Mehta R, Collins J, Austin D, Swift B. Population dose-response-time analysis of itch reduction and patient-reported tolerability supports phase III dose selection for linerixibat. Clin Pharmacol Ther. 2024;115(2):288\u2013298. https:\/\/doi.org\/10.1002\/cpt.3103","DOI":"10.1002\/cpt.3103"},{"key":"ref40","unstructured":"41.\tUS Food and Drug Administration. LIVMARLI (maralixibat) tablets and oral solution [package insert]. FDA; 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/219485s000lbl.pdf. Accessed December 8, 2025."},{"key":"ref41","unstructured":"42.\tEuropean Medicines Agency. Livmarli (maralixibat) \u2013 EPAR product information. EMA; 2022. https:\/\/www.ema. europa.eu\/en\/documents\/product-information\/livmarli-epar-product-information_en.pdf. Accessed December 8, 2025."},{"key":"ref42","unstructured":"43.\tUS Food and Drug Administration. Odevixibat (Bylvay) capsules and oral pellets [package insert]. FDA; 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/215498s006lbl.pdf. Accessed December 8, 2025."},{"key":"ref43","unstructured":"44.\tEuropean Medicines Agency. Bylvay (odevixibat) \u2013 EPAR. EMA; 2025. https:\/\/www.ema.europa.eu\/en\/medicines\/ human\/EPAR\/bylvay. Accessed December 8, 2025."},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"45.\tKamimura K, Yokoo T, Kamimura H, et al. Long-term efficacy and safety of nalfurafine hydrochloride on pruritus in chronic liver disease patients: patient-reported outcome based analyses. PLoS One. 2017;12(6):e0178991. https:\/\/ doi.org\/10.1371\/journal.pone.0178991","DOI":"10.1371\/journal.pone.0178991"}],"container-title":["Drugs in Context"],"original-title":[],"link":[{"URL":"https:\/\/www.drugsincontext.com\/wp-content\/uploads\/2026\/05\/dic.2025-12-3.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:22:07Z","timestamp":1790245327000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.drugsincontext.com\/new-and-emerging-treatments-for-pbc-related-pruritus"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":45,"URL":"https:\/\/doi.org\/10.7573\/dic.2025-12-3","relation":{},"ISSN":["1740-4398"],"issn-type":[{"value":"1740-4398","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"article-number":"dic.2025-12-3"}}